Ellen J. Scherl, M.D.




   Peer Reviewed Articles:

1.   Thung SN, Scherl E, Gerber MA. Hepatitis In Patients With AIDS. Hepatology, 3 (5): 864-864


2.   Scherl EJ, Fabry TL. Pseudodiverticula Secondary To Injection Sclerotherapy. Journal of

Clinical Gastroenterology, 5 (5): 401-403 1983.

3.   Cohen LB, Korsten MA, Scherl EJ, Velez ME, Fisse RD, Arons EJ. Bacteremia After

Endoscopic Injection Sclerosis. Gastrointestinal Endoscopy, 29 (3):198-200 1983.

4.   Simon C, Cohen L, Scherl E, Waye JD, Korsten MA. Esophageal Motility And Symptoms After

Endoscopic Injection Sclerotherapy. Gastrointestinal Endoscopy, 29 (2): 192-192 1983.

5.   Scherl EJ, Fabry TL. Pseudodiverticula After Esophageal Sclerotherapy. Gastrointestinal

Endoscopy, 29 (2): 192-192 1983.

6.   Scherl E, Siegel F, Geller S, Waye J. Gastrointestinal Manifestations Of Acquired

Immunodeficiency Syndrome (AIDS). Gastroenterology, 86 (5): 1235-1235 1984.

Waitman AM, Grant DZ, Scherl EJ, Chateau FZ. Laser Endoscopy - Beth-Israel Experience 250

Patients. Gastrointestinal Endoscopy, 31 (2): 160-161 1985.

7.   Cohen LB, Simon C, Korsten MA, Scherl EJ, Skorniky J, Guelrud MB, Waye JD. Esophageal

Motility And Symptoms After Endoscopic Injection Sclerotherapy. Digestive Diseases And

Sciences, 30 (1): 29-32 1985.

8.   Waitman AM, Grant DZ, Scherl EJ, Brettholz EM, Chateau F. Neodynium-Yag (Nd-

Yag) Laser In The Treatment of 78 Patients With Malignant Dysphagia. Gastrointestinal

Endoscopy, 34 (2): 183-184 Mar-Apr 1988.

9.   Bayless T, Drossman D, Scherl EJ. Helping Your IBD Patient Help Himself. Patient Care; Oct

15 1988: 139-156.

10.   Grant D, Scherl EJ, Waitman A, and Chateau F. Laser Therapy and Vascular Abnormalities.

Therapeutic Gastrointestinal Endoscopy 1990; Steven Silvis (Ed):151-174.

11.   Kelfen D, Laufer I, Leichman L, Orringer M, Rich T, and Scherl EJ. Alarming Trends in

Esophageal Carcinoma. Patient Care; Oct 15, 1992: 72-122.

12.   Goldman IS, Snady H, Waye JD, Scherl E, Morrissey K, Forde KA. Cecal photo-documentation:

Reliable when you are there, unreliable when you are not. Gastrointestinal Endoscopy, 43 (4):

301-301 Apr 1996

13.   Scherl E. The mysteries within: A surgeon reflects on medical myths.

American Book Review, 22 (2): 28-28 Jan-Feb 2001.

14.   Friedman S, Marion JF, Scherl EJ, Rubin P, Present DH. Intravenous Cyclosporine For

Refractory Pyoderma Gangrenosum Complicating Inflammatory Bowel Disease.

Inflammatory Bowel Diseases, 7 (1): 1-7, Feb 2001.

15.   Persley K, Scherl E, Rubin P. Avoidance of steroids by the early use of infliximab and 6-

mercaptopurine in an adolescent with active Crohn's colitis. American Journal of

Gastroenterology, 96 (12): 3444-3445 Dec 2001

16.   Chutkan RK, Scherl E, Waye JD. Colonoscopy in inflammatory bowel disease.

Gastrointest Endosc Clin N Am. 2002 Jul;12(3):463-83, viii. Review.

17.   Scherl EJ. Irritable-inflammatory bowel disease: recognizing a new overlap syndrome

and an enigma wrapped inside a puzzle. Inflamm Bowel Dis, 8(5):373-4 Sep 2002.

18.   Scherl, E, Subbaramaiah, K. Optimization and Individualization of Thiopurine Therapy

In Inflammatory Bowel Disease: The Great Variability Among Drug Responses. Pharmacogenomics Journal, 3: 66-68, 2003.

19.   Scherl, E, Frissora, CL. Irritable Bowel Syndrome Genophenomics: Correlation of Serotonin-

transporter Polymorphisms and Alosetron Response. Pharmacogenomics Journal, 3: 64-65,


20.   Subbaramaiah K, Yoshimatsu K, Scherl E, Das KM, Glazier KD, Golijanin D, Soslow

RA, Tanabe T, Naraba H, Dannenberg AJ. Microsomal prostaglandin E synthase-1 is

over expressed in inflammatory bowel disease. Evidence for involvement of the

transcription factor Egr-1. Epub Jan 1 2004. J Biol Chem, 279(13):12647-58, Mar 26


21.   Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH.

The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients.

Am J Gastroenterol, 99(4):656-61, Apr 2004.

22.   Nilubol N, Scherl E, Bub DS, Gorfine SR, Marion J, Harris MT, Kornbluth A, Lichtiger

S, Rubin P, George J, Chapman M, Harpaz N, Present D, Tejero C, Bodian C, Bauer JJ.

Mucosal dysplasia in lleal pelvic pouches after restorative proctocolectomy. Diseases of

The Colon & Rectum, 48 (3): 627-628 Mar 2005

23.   Thevarajah S, Polaneczky M, Scherl EJ, Frissora CL. Hormonal Influences on the

Gastrointestinal Tract and Irritable Bowel Syndrome. Practical Gastroenterology,

Treatment of Irritable Bowel Syndrome, Series #7: 62 – 74, May 2005.

24.   Yang A, Chen Y, Scherl E, Neugut AI, Bhagat G, and Green PHR. Inflammatory

Bowel Disease in Patients with Celiac Disease. Inflammatory Bowel Diseases, 11 (6): 528 – 32

Jun 2005.

25.   Jahraus CD, Rubin DT, Scherl EJ, Bettenhausen D. Inflammation’s Role in Rectal

Cancer Following Prostate Radiotherapy, and Emerging Evidence for a Protective Role

   for Balsalazide. Gastroenterology, 129 (2): 770 – 772 Aug 2005.


26.   Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E. Case Report: Lymphoma Arising in an Ileal Pouch Anal Anastomosis After Immunomodulatory Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2006, 4:1030-1034. August 2006.

27.   Poppers D, Scherl E. Evolution in the Pharmacogenetics and Pharmacogenomics of Inflammatory Bowel Disease – Order Slowly Rises from the Chaos. Current Pharmacogenomics; September 2006.

28.   Present DH, Lichtenstein GR, Scherl EJ. Emerging Issues in Ulcerative Colitis and Proctitis.

Gastroenterology and Hepatology, vol. 2 (9), supp. 11; Sept 2006.

29.   Nilubol N, Scherl E, Bub DS, Gorefine SR, Marion J, Harris MT, Kornbluth A, Lichtiger S, Rubin P, George J, Chapman M, Harpaz N, Present D, Bauer J. Mucosal Dysplasia in Ileal Pelvic Pouches after Restorative Proctocolectomy. Diseases of the Colon & Rectum; Winter 2006.

30.    Scherl E., Review in Inflammatory Bowel Diseases, Selected Summaries. Bacteria, Bugs, and BID Rifaximin for Crohn’s Disease, P.1-2.

31.    Lichtenstein, GR., Scherl E. 5-ASA Therapy in Management of Ulcerative Colitis Patients, Gastroenterology and Hepatology, Volume 3, Issue 3, Supplement 11, p.3-16; March 2007.

32.   Scherl E. 5-ASA Pharmacokinetics, Gastroenterology and Hepatology, Volume 3, Issue 3, Supplement 11, p.7-8; March 2007.


1.   Scherl, EJ, and Fabry, T, "Pseudodiverticula Post Sclerotherapy". Abstract in Journal of Clinical

Gastroenterology; 5:401-403, 1983.

2.   Simon, C, Cohen, L, Scherl, EJ, Waye, JD, Korsten, M. Esophageal Motility Following Injection Sclerotherapy. Gastrointestinal Endoscopy May 1983; Abstract.

3.   Rubin PH, Chapman ML, Scherl E, Sachar DB, Stamaty C, Present DH. Clarithromycin in active Crohn's disease (CD): Preliminary results of open label pilot study. Gastroenterology, 110 (4): A1005-A1005 Suppl. S Apr 1996.

4.   Friedman S, Marion JF, Scherl E, Rubin P, Present DH. The treatment of choice for pyoderma

gangrenosum complicating IBD - Intravenous Cyclosporine. Gastroenterology, 112 (4): A975-

A975 Suppl. S Apr 1997

5.   Toy LS, Campbell NA, Weiss AA, Scherl EJ, Mayer L. Defective gp180 expression in

the buccal mucosa of patients with ulcerative colitis but not with Crohn's disease.

Gastroenterology, 114 (4): G4504 Part 2 Suppl. S Apr 15 1998.

6.   Korzenik JR, Robert ME, Bitton A, Robinson M, Scherl EJ, Fisher RL, Binder HJ. A multi-center, randomized, controlled trial of heparin for the treatment of ulcerative colitis. Gastroenterology, 116 (4): G3264 Part 2 Apr 1999.

7.   Toy LS, Scherl EJ, Kraus TA, Mayer L. Defective GP180 expression in mono-zygotic twins

discordant for ulcerative colitis. Gastroenterology, 116 (4): G3619 Part 2 Apr 1999.

8.   Toy LS, Marion JF, Scherl EJ, Chapman ML, Present DH. Short term Infliximab toxicity in Crohn's disease. Gastroenterology, 118 (4): 2973 Part 1 Suppl. 2 Apr 2000.

9.   Toy LS, Scherl EJ, Kornbluth A, Marion JF, Greenstein AJ, Agus S, Gerson C, Fox N, Present DH. Complete bowel obstruction following initial response to Infliximab therapy for Crohn's disease: A series of a newly described complication. Gastroenterology, 118 (4): 2974 Part 1 Suppl. 2 Apr 2000.

10.   Toy LS, Marion JF, Scherl EJ, Chapman ML, Bodian C, Present DH. Infliximab therapy for Crohn's disease fistulae: Number of infusions required for response and time to relapse. Gastroenterology, 118 (4): 2975 Part 1 Suppl. 2 Apr 2000

11.   Marion JF, Bodian C, Lisa T, Chapman ML, Scherl EJ, Present DH. TNF micro-satellite

Polymorphism does not predict response to infliximab in patients with Crohn's disease.

Gastroenterology, 118 (4): 3596 Part 1 Suppl. 2 Apr 2000.

12.   Nilubol N, Bauer JJ, Gorfine SR, Scherl E, Kornbluth AA, Lichtiger S, Rubin PH, George J,

Chapman ML, Harpaz N, Tejero C, Present DH. In search of ileal mucosal dysplasia: A

prospective study of 138 pelvic pouch patients recalled one or more years following restorative

proctocolectomy. Gastroenterology, 120 (5): 2405 Suppl. 1 Apr 2001.

13.   Moskovitz D, Scherl EJ, Chapman ML, Marion JF, Rubin PH, Present DH. 5-ASA Drugs

Metronidazole, Ciprofloxacin, Prednisone, 6 Mercaptopurine and Azathioprine use

in Pregnant Patients with Inflammatory Bowel Disease. Journal of American College of

Gastroenterologists; abstract in press.

14.   Lodhavia PJ, Scherl EJ. Efficacy of infliximab in the treatment of refractory pouchitis. American Journal of Gastroenterology, 97 (9): 548 Suppl. S Sep 2002.

15.   Kim MK, Scherl E, Coleman M. Lymphoma of the pouch after IPAA for medically refractory ulcerative colitis. American Journal of Gastroenterology, 99 (10): S184-S184 568 Suppl. S Oct 2004

16.   Bosworth BP, Schnoll-Sussman F, Scherl, E. Video capsule endoscopy diagnosis of oxaliplatin-

induced enteritis in a patient with X-ray negative Crohn's disease. American Journal of

Gastroenterology, 99 (10): S186-S187 Suppl. S Oct 2004.

17.   Bosworth BP, Scherl EJ. A novel non-absorbable antibiotic (rifaximin) in the treatment of moderate to severe Crohn's disease. Gastroenterology, 128 (4): A576-A576 Suppl. 2 Apr 2005

18.   Weine DM, Bosworth BP, Poppers DM, Scherl EJ. The Role Of Serologic Markers In Predicting Infliximab Response In Ulcerative Colitis. Gastroenterology, submitted for DDW Supp Apr 2006.

19.   Scherl EJ. The Gut-Selective Antibiotic Rifaximin in the Treatment of Refractory Solitary Rectal

Ulcer: A Case Report. Gastroenterology, submitted for DDW Supp Apr 2006.

20.   Sandborn, W., Fagan, B, Fedorak, R., Scherl, E., Fleischer, M., Katz, S., Johanns, J., Blank, M., Rutgeertz, P. A Multicenter Randomzed Phase 2A Study of Human Monoclonal Antibody to IL-12/23 p40 (Cnto1275) in Patients with Moderately to Severely Active Crohn’s Disease. Gastroenterol, 2007: 132;4 (Suppl 2) A272 (Page A-51).

Books, Book Chapters and Reviews:

1.   Scherl EJ, Sachar DB. Crohn's Disease of the Small Intestine. Gastroenterology and Hepatology: The Comprehensive Visual Reference, Series ed. Mark Feldman. Churchill Livingston Ford LVA 1997; 7.1-7.22.

2.   Scherl E, Weine D, etal. Pocket Guide to Inflammatory Bowel Disease. eds. Sunanda Kane,

University of Chicago and Marla Dubinsky, Cedars Sinai Medical Center. Cambridge University

Press 2005.

3.   Scherl EJ, Weine DM, Bosworth B, Green PH. Medical Therapy of Gastroduodenal Crohn’s Disease. In: Lichtenstein GR, ed. Inflammatory Bowel Disease: The complete

guide to medical management. Slack, Inc. (in press).

Back to topBack To Top